Effects of somatostatin on insulin and glucagon in patients with insulinoma
- 1 July 1979
- journal article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 2 (3) , 257-260
- https://doi.org/10.1007/bf03350412
Abstract
Effects of somatostatin on fasting and arginine- or tolbutamide-stimulated insulin release were studied in four patients with insulinoma. Somatostatin (bolus or bolus + infusion) reduced fasting insulin values in all patients; insulin response to tolbutamide was partially reduced in two patients; somatostatin bolus impaired the insulin response to arginine. Fasting glucagon levels and glucagon response to arginine were also reduced by somatostatin. These results indicate the potential usefulness of somatostatin in the diagnosis of insulinoma even if its effect on insulin is only partial.Keywords
This publication has 16 references indexed in Scilit:
- Somatostatin inhibition of insulin secretion in insulin-producing tumorsMetabolism, 1976
- SOMATOSTATIN AND INSULINOMAThe Lancet, 1975
- Somatostatin inhibits insulin and glucagon release by monolayer cell cultures of rat endocrine pancreasLife Sciences, 1974
- SPECIFIC INHIBITION BY SOMATOSTATIN OF GROWTH HORMONE RELEASE AFTER HYPOGLYCAEMIA IN NORMAL MANClinical Endocrinology, 1974
- Direct inhibition of insulin secretion by synthetic somatostatinBiochemical and Biophysical Research Communications, 1974
- Somatostatin: Hypothalamic Inhibitor of the Endocrine PancreasScience, 1974
- Growth Hormone Release Inhibiting Hormone in AcromegalyBMJ, 1974
- INHIBITION OF INSULIN SECRETION BY SOMATOSTATINThe Lancet, 1973
- ACTION OF GROWTH-HORMONE-RELEASE INHIBITORY HORMONE IN HEALTHY MEN AND IN ACROMEGALYThe Lancet, 1973
- Pancreatic Glucagon Secretion in Normal and Diabetic SubjectsThe Lancet Healthy Longevity, 1969